Contact Information: FOR FURTHER INFORMATION, CONTACT: Michael Brennan Chairman Micro Imaging Technology, Inc. Email: Telephone: (805) 557-0614
MIT Rapidly Identifies the Life-Threatening Bacteria MRSA
| Source: Micro Imaging Technology, Inc.
SAN CLEMENTE, CA--(Marketwire - September 11, 2007) - Micro Imaging Technology (OTCBB : MMTC )
announced that its laser-based, microbial rapid identification system, the
MIT 1000, is able to rapidly identify the life-threatening bacterial strain
Methicillin Resistant Staphylococcus aureus (MRSA).
Staphylococcus aureus or 'Staph,' the most common cause of Staph
infections, is a bacterium frequently living on the skin or in the nose of
a person and can cause a range of illnesses from minor skin infections,
like pimples, boils, and abscesses, to life-threatening diseases, such as
pneumonia, meningitis, and toxic shock syndrome. Some strains of Staph
bacteria have become resistant to common antibiotics, including
methicillin, oxacillin, penicillin and amoxicillin. These bacteria have
become known as Methicillin Resistant Staphylococcus aureus or MRSA.
Staph infections, including MRSA, occur most frequently among
immunocompromised persons and are a rising problem for both hospitals and
healthcare facilities. Hospital staff, visitors, patients, and even
inanimate objects can all be reservoirs for a MRSA infection. Often MRSA
carriers do not develop an infection, so they do not receive or require
treatment. However, patients with weakened immune systems have a 30 - 60%
risk of infection once the bacteria are introduced by the carrier and have
colonized.
"The MIT 1000 system went into limited production in July 2007 and,
including MRSA, contains 23 different bacterial species in its
identification library. The product's ability to identify MRSA at this
time was beyond our expectations. We will now seek a partner to help us
expand system performance so that it can repetitively differentiate MRSA
from non-resistant Staph bacteria. Our goal is to complete this task by
year end," stated Michael Brennan, MIT Chairman.
Mr. Brennan further stated, "We are excited that the MIT 1000 system's
rapid identification capability could play an important role to quickly
identify MRSA carriers and subsequently reduce spreading these dangerous
bacteria."
Micro Imaging Technology (MIT)
The Company has developed and patented a laser-based technology for rapid
microbe detection and identification. The system measures scattered light
intensity as individual microbes pass through a laser beam. The intensity
pattern of the scattered light is a direct consequence of the size, shape,
and external and internal optical characteristics of the microbe. The MIT
System is non-biological and does not rely on biological agents,
conventional chemical processing, fluorescent tags, gas chromatography or
DNA analysis.
MIT has demonstrated the ability to detect and identify, within several
minutes, the microbes Escherichia coli, Listeria, Salmonella,
Staphylococcus aureus, Shigella and other pathogenic bacteria. The
identification process has been verified by North American Science
Associates, Inc. (NAMSA), an independent, internationally recognized
biological testing laboratory. The Test Report, in the Company's opinion,
demonstrated the accuracy, speed and efficiency of the MIT system over
conventional processes and is available from the Company.
This release contains statements that are forward looking in nature.
Statements that are predictive in nature, that depend upon or refer to
future events or conditions or that include words such as "expects,"
"anticipates," "intends," "plans," "believes," "estimates," and similar
expressions are forward-looking statements. These statements are made
based upon information available to the Company as of the date of this
release, and we assume no obligation to update any such forward-looking
statements. These statements are not guarantees of future performance and
actual results could differ materially from our current expectations.
Factors that could cause or contribute to such differences include, but are
not limited to dependence on suppliers; short product life cycles and
reductions in unit selling prices; delays in development or shipment of new
products; lack of market acceptance of our new products or services;
inability to continue to develop competitive new products and services on a
timely basis; introduction of new products or services by major
competitors; our ability to attract and retain qualified employees;
inability to expand our operations to support increased growth; and
declining economic conditions, including a recession. These and other
factors and risks associated with our business are discussed from time to
time within our filings with the Securities and Exchange Commission.